Lianne Gensler, MD
Rheumatology · San Francisco, CANPI 1780781369
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $194,246 of the $295,836 with a category attached, or 65.7%. It is spread thinly across 15 manufacturers, the largest accounting for just 21.5%. Reporting peaked in 2019 at $102,517 and has fallen 84.8% since, to $15,541 in 2025. Among rheumatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $1652.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis Pharma AG$64K
- UCB, Inc.$51K
- UCB SA$48K
- Novartis$44K
- Pfizer$31K
- GSK$18K
- plus $39K from 9 others
Across 71 payments — averaging $10,444 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$355K
- UCB, Inc.$308K
- Pfizer$57K
- UCB GmbH$17K
- AbbVie$3K
- Amgen$2K
What the payments were for
- Consulting fees$194,24666%
- Speaking & faculty fees$46,55516%
- Travel & lodging$52,58318%
- Food & beverage$2,3521%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis Pharma AG | 22 | $63,646 |
| UCB, Inc. | 39 | $51,154 |
| UCB SA | 30 | $48,400 |
| Novartis | 17 | $44,451 |
| Pfizer | 7 | $30,967 |
| GSK | 14 | $17,998 |
| Janssen Scientific Affairs, LLC | 8 | $12,428 |
| Eli Lilly | 2 | $7,827 |
| Johnson & Johnson | 20 | $4,851 |
| UCB Biosciences Inc. | 5 | $4,132 |
| AbbVie | 7 | $3,673 |
| Janssen Research & Development, LLC | 3 | $2,795 |
| Gilead | 1 | $2,000 |
| Fresenius Kabi USA, LLC | 1 | $1,440 |
| Amgen | 3 | $74 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COSENTYX$53,812
- AIN457F_COSENTYX_IMMUNOLOGY$44,647
- XELJANZ$29,467
- Bimzelx$27,378
- Cimzia$20,535
- Tremfya$11,183
- SIMPONI ARIA$10,403
- SECUKINUMAB_COSENTYX_DERMATOLOGY$7,087
- STELARA$5,731
- REMICADE$3,881
- ILARIS$1,947
- Enbrel$1,500
- Rinvoq$1,000
- SIMPONI$810
- Humira$500
How this compares
$295,836 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 33 | $281,981 |
| Humira(Cf) PenAdalimumab | 30 | $249,718 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $144,977 |
| RinvoqUpadacitinib | 25 | $143,738 |
| Cosentyx (2 Syringes)Secukinumab | 14 | $96,425 |
| SimponiGolimumab | 12 | $76,488 |
| InflectraInfliximab-Dyyb | 13 | $48,099 |
| Yusimry(Cf) PenAdalimumab-Aqvh | 12 | $20,558 |
| Celecoxib | 54 | $3,830 |
| Hydroxychloroquine Sulfate | 19 | $728 |
| Clobetasol Propionate | 13 | $701 |
| MethotrexateMethotrexate Sodium | 15 | $247 |
| Azathioprine | 12 | $166 |
| Diclofenac Sodium | 18 | $160 |
| Omeprazole | 11 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $3,673 | $143,73825 claims |
| NovartisCosentyx (2 Syringes) | $44,451 | $96,42514 claims |
| Johnson & JohnsonSimponi | $4,851 | $76,48812 claims |
| PfizerInflectra | $30,967 | $48,09913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 rheumatology providers in California.
Other rheumatology in San Francisco
- Sudhakar TumuluriSan Francisco$2.8M
- Arthur WeissSan Francisco$100K
- David WofsySan Francisco$82K
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.